Advanced search
Publication Cover
Future Cardiology Volume 8, 2012 - Issue 4
Submit an article Journal homepage
140
Views
0
CrossRef citations to date
0
Altmetric
Drug Evaluation

Atopaxar: A Review of Its Mechanism of Action and Role in Patients With Coronary Artery Disease

Fabiana Rollini1 University of Florida College of Medicine-Jacksonville 655 West 8th Street JacksonvilleFL32209USA. [email protected]
,
Antonio Tello-Montoliu1 University of Florida College of Medicine-Jacksonville 655 West 8th Street JacksonvilleFL32209USA. [email protected]
&
Dominick J Angiolillo1 University of Florida College of Medicine-Jacksonville 655 West 8th Street JacksonvilleFL32209USA. [email protected]
Pages 503-511 | Published online: 07 Aug 2012

References

  • Libby P . Current concepts of the pathogenesis of the acute coronary syndromes. Circulation, 104, 365–372 (2001).
  • Braunwald E , AngiolilloD, BatesEet al. The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary intervention. Clin. Cardiol. , 31, 17–20 (2008).
  • Angiolillo DJ , UenoM, GotoS. Basic principles of platelet biology and clinical implications. Circ. J., 74, 597–607 (2010).
  • Furie B , FurieBC. Mechanisms of thrombus formation. N. Engl. J. Med., 359, 938–949 (2008).
  • Davi G , PatronoC. Platelet activation and atherothrombosis. N. Engl. J. Med., 357, 2482–2494 (2007).
  • Offermanns S . Activation of platelet function through G protein-coupled receptors. Circ. Res., 99, 1293–1304 (2006).
  • Meadows TA , BhattDL. Clinical aspects of platelet inhibitors and thrombus formation. Circ. Res., 100, 1261–1275 (2007).
  • Angiolillo DJ , CapodannoD, GotoS. Platelet thrombin receptor antagonism and atherothrombosis. Eur. Heart J., 31, 17–28 (2010).
  • Steinhoff M , BuddenkotteJ, ShpacovitchVet al. Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response. Endocr. Rev. , 26, 1–43 (2005).
  • Patrono C et al. , García Rodríguez LA, Landolfi R Low-dose aspirin for the prevention of atherothrombosis. N. Engl. J. Med., 353, 2373–2383 (2005).
  • Wallentin LC . Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. Research Group on instability in coronary artery disease in Southeast Sweden. J. Am. Coll. Cardiol., 18, 1587–1593 (1991).
  • Baigent C , BlackwellL, CollinsRet al.; Antithrombotic Trialists‘ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomized trials. Lancet, 373, 1849–1860 (2009).
  • Anderson JL , AdamsCD, AntmanEMet al. 2011 Writing group members; ACCF/AHA task force members. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation , 123, 426–579 (2011).
  • Levine GN , BatesER, BlankenshiJCet al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines and the Society for cardiovascular angiography and interventions. J. Am. Coll. Cardiol. , 58, E44–E122 (2011).
  • Vivas D , AngiolilloDJ. Platelet P2Y12 receptor inhibition: an update on clinical drug development. Am. J. Cardiovasc. Drugs, 10, 217–226 (2010).
  • Bertrand ME , RupprechtHJ, UrbanP et al.; CLASSICS Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation, 102, 624–629 (2000).
  • Angiolillo DJ , Fernandez-OrtizA, BernardoEet al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J. Am. Coll. Cardiol. , 49, 1505–1516 (2007).
  • Angiolillo DJ , FerreiroJL. Platelet adenosine diphosphate P2Y12 receptor antagonism: benefits and limitations of current treatment strategies and future directions. Rev. Esp. Cardiol., 63, 60–76 (2010).
  • Capodanno D , DharmashankarK, AngiolilloDJ. Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist. Expert Rev. Cardiovasc. Ther., 8, 151–158 (2010).
  • Tomasello SD , Tello-MontoliuA, AngiolilloDJ. Prasugrel for the treatment of coronary thrombosis: a review of pharmacological properties, indications for use and future development. Expert Opin. Invest. Drugs, 20, 119–133 (2011).
  • Wiviott SD , BraunwaldE, McCabeCHet al.; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med., 357, 2001–2015 (2007).
  • Wallentin L , BeckerRC, BudajAet al.; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med., 361, 1045–1057 (2009).
  • Mehran R , PocockS, NikolskyEet al. Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials. JACC Cardiovasc. Interv. , 4, 654–664 (2011).
  • Michelson AD , FrelingerALet al. 3rd, Braunwald E ; TRITON-TIMI 38 Investigators. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur. Heart J., 30, 1753–1763 (2009).
  • Storey RF , AngiolilloDJ, PatilSBet al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J. Am. Coll. Cardiol. , 56, 1456–1462 (2010).
  • Coughlin SR . Protease-activated receptors in hemostasis, thrombosis and vascular biology. J. Thromb. Haemost., 3, 1800–1814 (2005).
  • Kahn ML , Nakanishi-MatsuiM, ShapiroMJet al. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J. Clin. Invest. , 103, 879–887 (1999).
  • Ueno M , FerreiroJL, AngiolilloDJ. Mechanism of action and clinical development of platelet thrombin receptor antagonists. Expert Rev. Cardiovasc. Ther., 8, 1191–1200 (2010).
  • Xu WF , AndersenH, WhitmoreTEet al. Cloning and characterization of human protease-activated receptor 4. Proc. Natl Acad. Sci. USA , 95, 6642–6646 (1998).
  • Lova P , CanobbioI, GuidettiGFet al. Thrombin induces platelet activation in the absence of functional protease activated receptors 1 and 4 and glycoprotein Ib-IX-V. Cell Signal. , 22, 1681–1687 (2010).
  • Henriksen RA , HanksVK. PAR-4 agonist AYPGKF stimulates thromboxane production by human platelets. Arterioscler. Thromb. Vasc. Biol., 22, 861–866 (2002).
  • Covic L , SinghC, SmithHet al. Role of the PAR4 thrombin receptor in stabilizing platelet-platelet aggregates as revealed by a patient with Hermansky–Pudlak syndrome. Thromb. Haemost. , 87, 722–727 (2002).
  • Lova P , CampusF, LombardiRet al. Contribution of protease-activated receptors 1 and 4 and glycoprotein Ib-IX-V in the G(i)-independent activation of platelet Rap1B by thrombin. J. Biol. Chem. , 279, 25299–25306 (2004).
  • Smith CC , WilsonAP, PrichardBNet al. Stimulus-induced release of endogenous catecholamines from human washed platelets. Clin. Sci. (Lond.) , 70, 495–500 (1986).
  • Henn V , SlupskyJR, GrafeMet al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature , 391, 591–594 (1998).
  • Offermanns S , ToombsCF, HuYHet al. Defective platelet activation in G α(q)-deficient mice. Nature , 389, 183–186 (1997).
  • Andersen H , GreenbergDL, FujikawaKet al. Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity. Proc. Natl Acad. Sci. USA , 96, 11189–11193 (1999).
  • Goldsack NR , ChambersRC, DabbaghKet al. Thrombin. Int. J. Biochem. Cell. Biol. , 30, 641–646 (1998).
  • Leger AJ , JacquesSL, BadarJet al. Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis. Circulation , 113, 1244–1254 (2006).
  • Chintala M , AhnH, FosterCet al. Antithrombotic effects of SCH 205831: a potent, selective and orally active antagonist of the PAR-1 thrombin receptor. J. Thromb. Haemost. , 3(Suppl. 1), (2005) (Abstract OR286).
  • Chackalamannil S , XiaY, GreenleeWJet al. Discovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agents. J. Med. Chem. , 48, 5884–5887 (2005).
  • Chintala M , StronyJ, YangBet al. SCH 602539, a protease-activated receptor-1 antagonist, inhibits thrombosis alone and in combination with cangrelor in a Folts model of arterial thrombosis in cynomolgus monkeys. Arterioscler. Thromb. Vasc. Biol. , 30, 2143–2149 (2010).
  • Kato Y , KitaY, Hirasawa-TaniyamaYet al. Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig. Eur. J. Pharmacol. , 473, 163–169 (2003).
  • Kogushi M , MatsuokaT, KawataTet al. The novel and orally active thrombin receptor antagonist E5555 (atopaxar) inhibits arterial thrombosis without affecting bleeding time in guinea pigs. Eur. J. Pharmacol. , 657, 131–137 (2011).
  • Kogushi M , YokohamaH, KitamuraSet al. Effects of E5555, a protease activated receptor-1 antagonist, on the inflammatory markers in vitro. J. Thromb. Haemost. , 5(Suppl. 2), (2007) (Abstract P-M-059).
  • Kai Y , HiranoK, MaedaYet al. Prevention of the hypercontractile response to thrombin by proteinase-activated receptor-1 antagonist in subarachnoid hemorrhage. Stroke , 38, 3259–3265 (2007).
  • Hamilton JR , CornelissenI, CoughlinSR. Impaired hemostasis and protection against thrombosis in protease-activated receptor 4-deficient mice is due to lack of thrombin signaling in platelets. J. Thromb. Haemost., 2, 1429–1435 (2004).
  • Derian CK , DamianoBP, AddoMFet al. Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. J. Pharmacol. Exp. Ther. , 304, 855–861 (2003).
  • Matsuoka T , KogushiM, KawataTet al. Inhibitory effect of E5555, an orally active thrombin receptor antagonist, onintimal hyperplasia following balloon injury. J. Am. Coll. Cardiol. , 43, 68A (2004).
  • Marion A , ReyesJ, ChenHet al. Safety, pharmacokinetics, and pharmacodynamics of ascending multiple oral doses of a new protease activated receptor-1 inhibitor in healthy volunteers. Presented at: 35th Annual Meeting of the American College of Clinical Pharmacology. Cambridge, MA, USA, 17–19 September 2006.
  • Takeuchi M , KageyamaM, KitamuraSet al. Pharmacodinamics and safety of a novel protease activated receptor-1 antagonist E5555 in healthy volunteers. Eur. Heart J. , 28(Suppl. 1), (2007) (Abstract Vienna 264).
  • Serebruany VL , KogushiM, Dastros-PiteiDet al. The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease. Thromb. Haemost. , 102, 111–119 (2009).
  • Goto S , OgawaH, TakeuchiMet al.; J-LANCELOT (Japanese-Lesson from Antagonizing the Cellular Effect of Thrombin) Investigators. Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease. Eur. Heart J., 31, 2601–2613 (2010).
  • O‘Donoghue ML , BhattDL, WiviottSDet al.; LANCELOT-ACS Investigators. safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes the lessons from antagonizing the cellular effects of thrombin-acute coronary syndromes trial. Circulation, 123, 1843–1853 (2011).
  • Wiviott SD , FlatherMD, O‘DonoghueMLet al.; LANCELOT-CAD Investigators. Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of thrombin-coronary artery disease trial. Circulation, 123, 1854–1863 (2011).
  • Tricoci P , HuangZ, HeldCet al.; The TRACER Investigators. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N. Engl. J. Med., 366, 20–33 (2012).
  • Morrow DA , BraunwaldE, BonacaMPet al.; The TRA 2P–TIMI 50 Steering Committee and Investigators. Vorapaxar in the secondary prevention of atherothrombotic events. N. Engl. J. Med., 366(15), 1404–1413 (2012).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.